PDF(Pubmed)
Abstract：
Sickle cell anemia (SCA), the most common form of sickle cell disease (SCD), is a genetic blood disorder. Red blood cells break down prematurely, causing anemia and often blocking blood vessels, leading to chronic pain, organ damage, and increased infection risk. SCD arises from a single-nucleotide mutation in the β-globin gene, substituting glutamic acid with valine in the β-globin chain. This review examines treatments evaluated through randomized controlled trials for managing SCD, analyzes the potential of functional foods (dietary components with health benefits) as a complementary strategy, and explores the use of bioactive compounds as functional food ingredients. While randomized trials show promise for certain drugs, functional foods enriched with bioactive compounds also hold therapeutic potential. Further research is needed to confirm clinical efficacy, optimal dosages, and specific effects of these compounds on SCD, potentially offering a cost-effective and accessible approach to managing the disease.
摘要：
镰状细胞性贫血(SCA),镰状细胞病（SCD）最常见的形式，是遗传性血液病.红细胞过早分解,导致贫血并经常阻塞血管，导致慢性疼痛，器官损伤,增加感染风险。SCD起因于β-珠蛋白基因的单核苷酸突变,在β-珠蛋白链中用缬氨酸取代谷氨酸。这篇综述检查了通过随机对照试验评估的治疗方法，以管理SCD。分析功能食品（具有健康益处的饮食成分）作为补充策略的潜力，并探索了生物活性化合物作为功能性食品成分的用途。虽然随机试验显示了某些药物的前景，富含生物活性化合物的功能性食品也具有治疗潜力。需要进一步的研究来证实临床疗效，最佳剂量，以及这些化合物对SCD的具体影响，可能提供一种具有成本效益和可访问的方法来管理疾病。
